Neoplasia de localização primária desconhecida
Palavras-chave:
neoplasia de localização primária desconhecida, critérios clínicos, características biológicas, imunohistoquímica, tratamento, quimioterapiaResumo
As neoplasias de localização primária
desconhecida constituem um grupo heterogéneo de
tumores malignos que têm como denominador
comum as suas características biológicas.
Apresentam uma incidência de 2 a 3% e são mais
frequentes no homem com idade superior a 60 anos.
Em termos globais têm mau prognóstico, mas há
alguns subgrupos potencialmente curáveis que
devem ser identificados precocemente, de forma a
instituir uma terapêutica adequada. Os autores fazem
uma revisão do tema com objectivo de apresentar
uma metodologia diagnóstica e terapêutica que
permita uma abordagem prática deste grupo de neoplasias.
Downloads
Referências
Lembersky BC, Thomas LC. Metastases of unknown primary site. Med Clin N Am 1996; 80 (1): 153-171.
Greco FA, Hainsworth JD. Cancer of unknown primary site. In: De Vita VT, Hellman S, Rosenberg SA, ed. Cancer. Principles and
practice of oncology. Philadelphia: J.B. Lippincott Co 1997: 2423-2443.
Le Chevalier T, Cvitkovic E, Caille P. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302
consecutive autopsied patients. Arch Intern Med 1988; 148: 2035-2039.
Nystrom JS, Weiner JM, Wolf RM et al. Identifying the primary site in metastatic cancer of unknown origin. JAMA 1979; 241:
-383.
Stone RM. Metastatic cancer of unknown primary site. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, ed. Harrison’s principles of
internal medicine. New York: The MacGraw-Hill Companies Inc, 1998: 614-618.
Muir C. Cancer of unknown primary site. Cancer 1995; 75 (1): 354-356.
Abbruzzese JL, Lenzi R, Raber MN et al. The biology of unknown primary tumours. Semin Oncol 1993; 20: 238.
Ayoub JP, Hess KR, Abbruzzese MC. Unknown primary tumours metastatic to liver. J Clin Oncol 1998; 16 (6): 2105-2112.
Karsell PR, Sheedy PF, O’Connell MJ. Computed tomography in search of cancer of unknown origin. JAMA 1982; 248 (3): 340-
Mc Millan JH, Levine E, Stephens RH. Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown
primary site: a retrospective study. Radiology 1982; 143: 143-146.
Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM. Metastatic and histologic presentations in unknown
primary cancer. Semin Oncol 1977; 4: 53-58.
Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10: 912-922.
Azar HA, Espinoza CG, Richman AV, Saba SR, Wang T. “Undifferentiated” large cell malignancies: an ultrastructural and
immunocytochemical study. Hum Pathol 1982; 13: 323-333.
Hainsworth JD, Wright EP, Johnson DH, Davis BW, Greco FA. Poorly differentiated carcinoma of unknown primary site: clinical
usefulness of immunoperoxidase staining. J Clin Oncol 1991; 9:1931-1938.
Hales SA, Gatter KC, Heryet A, Masur DY. The value of immunocytochemistry in differentiating high-grade lymphoma
from other anaplastic tumours: a study of anaplastic tumours from 1940 to 1960. Leuk Lymphoma 1989; 1: 59-63.
Warnke RA, Gatter KC, Falini B, et al. Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. N Engl J
Med 1983; 309: 1275-1281.
Allhoff EP, Proppe KH, Chapman CM, Lin CW, Prout GR Jr. Evaluation of prostate specific acid phosphatase and prostate
specific antigen in identification of prostatic cancer. J Urol 1983; 129: 315-318.
Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993; 329 (4): 257-263.
Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site: a newly
recognised clinicopathologic entity. Ann Inter Med 1988; 109: 364-371.
Bosl GJ, Dmitrovsky E, Reuter V, Samaniego F, Murty VVVS, Chaganti RSK. A specific karyotypic abnormality in germ cell
tumours. (abst). Proc Am Soc Clin Oncol 1989; 8: 131.
Turc-Carel C, Philip I, Berger MP, Philip T, Lenoir GM. Chromosomal translocations in Ewing’s sarcoma. N Engl J Med
; 309: 497-498
Whang-Peng J, Triche TJ, Knutsen T, Miser J, Douglas EC, Israel MA. Chromosome translocation in peripheral neuroepithelioma.
N Engl J Med 1984; 311: 584-585.
Stewart JF, Tattersall MHN, Woods RL, Fox RM. Unknown primary adenocarcinoma: incidence of over investigation and
natural history. Br Med J 1979; 1: 1530-1533.
Bhatia SK, Saclarides TJ, Witt TR, Bonomi PD, Anderson KM, Economou SG. Hormone receptor studies in axillary metastases
from occult breast cancer. Cancer 1987; 59: 1170-1172.
Medini E, Medini AM, Lee CKK, Gapany M, Levitt SH. The management of metastatic squamous cell carcinoma in cervical
lymph nodes from an unknown primary. Am J Clin Oncol 1998; 21 (2): 121-125.
De Braud F, Al-Sarraf M. Diagnosis and management of squamous cell carcinoma of unknown primary tumour site of the neck.
Semin Oncol 1993; 20: 273-278.
Abbruzzese JL, Abbruzzese MC, Lenzi R et al. Analysis of a diagnostic strategy for patients presenting with tumours of
unknown origin. J Clin Oncol 1995; 13: 2094-2103.
Dalrymple JC, Bannatyne P, Russel P, et al. Extraovarian peritoneal serous papillary carcinoma: a clinicopathologic study
of 31 cases. Cancer 1989; 64: 110-115.
Hochster H, Wernz JC, Muggia FM. Intra-abdominal carcino-matosis with histologically normal ovaries. Cancer Treat Rep 1984; 68: 931-932.
Chen KT, Flam MS. Peritoneal papillary serous carcinoma with long-term survival. Cancer 1986; 58: 1371-1373.
Strnad CM, Grosh WW, Baxter J, et al. Peritoneal carcinomatosis of unknown primary site in women: a distinctive subset of adenocarcinoma. Ann Intern Med 1989; 111: 213-217.
Ransom DT, Patel SR, Keeney GL, Malkasian GD, Edmonson JH. Papillary serous carcinoma of the peritoneum: a review of 33
cases treated with platin-based chemotherapy. Cancer 1990; 66: 1091-1094.
Patel J, Nemoto T, Rosner D, Dao TL, Pickren JW. Axillary lymph node metastases from an occult breast cancer. Cancer 1981;
: 2923-2927.
Rosen PP. Axillary lymph node metastases in patients with occult non-invasive breast carcinoma. Cancer 1980; 46: 1298-1306.
Milliken ST, Tattersall MHN, Woods RL, et al. Metastatic adenocarcinoma of unknown primary site: a randomised study of
two combination chemotherapy regimens. Eur J Cancer Clin Oncol 1987; 23: 1645.
Van der Gaast A, Verweij J, Planting AST et al. 5-Fluorouracil, doxorubicin and mitomycin-C (FAM) combination chemotherapy
for metastatic adenocarcinoma of unknown primary. Eur J Cancer Clin Oncol 1988; 24: 765.
Weir L, Keane T, Cummings B et al. Radiation treatment of cervical lymph node metastases from an unknown primary: an
analysis of outcome by treatment volume and other prognostic factors. Rad Oncol 1995; 35: 206-211.
Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordoñez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly
differentiated adenocarcinoma of unknown origin: favourable subsets of patients with unknown primary carcinoma? J Clin Oncol
; 15 (5): 2056-2066
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
